Shares of Qiagen have rebounded after three years following a news report that the provider of biotech workflow solutions was evaluating strategic options, which include a potential sale.

MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

When the team knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the mutant EGFR protein.

A team at Johns Hopkins Medicine has focused their work on myelin development using oligodendrocytes to help study conditions like MS.

Immune signaling in IBD triggers tumor-promoting neutrophils which is linked to an increased risk of colorectal cancer.

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.

The discovery fundamentally changes the understanding of a structure in the avian eye that has been misinterpreted for centuries.

The so-called magneto-sensitive fluorescent proteins or MFPs, overcome key limitations of previous biological candidates for quantum sensors.

The new investment in the Holly Springs facility is on top of the initial commitment in May 2025, and groundbreaking in August 2025.

D printing is a good option for bioreactor production. The flexibility of the approach outweighs concerns about higher costs.

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...